(Photo source UK Parliament website. Used under Creative Commons).
The news that the UK will rejoin the €95.5 billion research fund has been met with widespread relief, but it’s a bittersweet story, finds Sarah Speight. Reaction from CMS, Arnold & Porter, Bird & Bird, HGF.
Today, the British scientific community woke to the news that the UK has finally rejoined Horizon Europe, the European Union’s €95.5 billion ($102 billion) research funding programme.
The collective sigh of relief is almost audible.
Following Brexit, which took effect in January 2020, the UK and the EU struggled to negotiate a deal to keep the UK signed up to Horizon. This was a huge blow to UK scientific research—especially since the UK is seen as a world leader in this field.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Horizon Europe, Brexit, UK, EU, European Commission, funding, innovation